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Background: Multiple dermatoﬁbromas (‘‘DFs”) are deﬁned by the presence of 15 lesions in the same patient or the development of
ﬁve to eight DFs over the period of 4 months. Fifty-six percent of multiple DFs are associated with other diseases. The most common
associated disease is systemic lupus erythematosus (‘‘SLE”) followed by immunodeﬁciency virus (‘‘HIV”) infection. Main observation:
We report a case of a 25-year-old Saudi Arab female with SLE on immunosuppressive drugs with multiple DFs. Conclusion: The most
common association with multiple DFs is SLE followed by HIV. Most of the patients with SLE were on immune suppressive medica-
tions. Dermatologists, rheumatologists, surgeons and internists should note that patients with SLE who are on immune suppressive med-
ications are at risk of developing multiple DFs.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A twenty ﬁve year old Saudi Arab female with systemic
lupus erythematosus (SLE) having an antinuclear antibody
1:320 homogenous pattern, double stranded DNA anti-
body recorded >1000 IU/ml, and anti-Smith antibodies
equal to 174 units. Anti-Ro/SSA antibodies and anti-La/
SSB antibodies were negative. The disease was controlledhttp://dx.doi.org/10.1016/j.jdds.2016.03.001
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Production and hosting by Elsevierwith prednisone 10 mg daily, tacrolimus 0.5 mg every
12 h, and hydroxychloroquine 200 mg daily. The patient
visited the dermatology clinic complaining of a new onset
of multiple asymptomatic skin growths over a period of
six months. On skin examination, six rounded brown nod-
ules were noted over the superior shoulder (Fig. 1), medial
and lateral arm, back and posterior thigh. Histopathologi-
cal examination of one of the lesions showed epidermal
hyperplasia, dermal proliferation of ﬁbroblasts, and histio-
cytes with intervening thick collagen bundles consistent
with dermatoﬁbroma (Figs. 2 and 3).2. Discussion
Dermatoﬁbroma also known as ﬁbrous histiocytoma is
a dermal tumor formed by proliferation of fusiform cells
in the dermis. The cells are a variable combination of
ﬁbroblasts, collagen, blood vessels and histiocytesehalf of King Saud University.
ommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Two rounded brown nodules on the shoulder.
Figure 2. Dermatoﬁbroma with overlying hyperplastic ep
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brown rounded ﬁrm papules ranging from 3 mm to 2 cm.
They can also be pink-red (32.8%), skin colored (23%),
or, in rare circumstances, blue in color (2.45%). The most
common location is the lower extremities of young females
(Han et al., 2011). When lateral pressure is applied to the
skin surrounding DFs, the lesions become depressed from
the level of the skin (dimple sign or Fitzpatrick’s sign)
(Naversen et al., 1993). The dermoscopic patterns of DFs
are variable with the most common being a central white
scar-like area with a delicate pigment network at the
periphery (Zaballos et al., 2008).
The histological variants include ﬁbrocollagenous DF
(40.1%) which is formed mainly from collagen and
ﬁbroblast-like cells in an irregular or whorled pattern,
histiocytic (13.1%) with angulated epithelioid cells,
cellular (11.5%) with larger numerous ﬁbroblasts that
can occasionally inﬁltrate fat, aneurysmal (7.4%) with
prominent pseudovascularity, angiomatous (6.5%) with
the presence of small branching vessels in a collagenous
stroma, sclerotic (6.5%) with hyalinized dense collagen,
monster (4.9%) with bizarre atypical giant cells, palisad-
ing (1.6%) with Verocay-like bodies resembling a
Schwannoma, and keloidal characterized by the presence
of thick collagen and multinucleated giant cells with
hemorrhage and hemosiderin deposits (Han et al., 2011;
Rapini, 2005). Typically, DFs express positivity for
actor XIIIa, HMGA1, and HMGA2 (high mobility
group AT-hook 1 and 2. CD34 is negative in DFs (Li
et al., 2004).ithelium (hematoxylin and eosin, 33 magniﬁcation).
Figure 3. Spindle cell proliferation in storiform pattern (hematoxylin and eosin, 197 magniﬁcation).
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Fifty percent of cases reported were more than 15 lesions.
However, less than this number with the same associations
was also reported. Five to eight DFs developing over the
period of 4 months is also included in this deﬁnition. The
term eruptive DFs is used when the lesions appear over a
4-month period.
Fifty-six percent of multiple DFs are associated with
disease. The commonest diseases include SLE (46%), fol-
lowed by immunodeﬁciency virus (HIV) infection (32%).
Most of patients with SLE were on immune suppressive
medications. Other diseases associated with multiple DFs
include myasthenia gravis, pemphigus vulgaris, Sjogren’s
syndrome, hydronephrosis, sarcoidosis and Se´zary syn-
drome (Niiyama et al., 2002a,b, 2001; Massone et al.,
2002; Tsunemi et al., 1995; Lu et al., 1997; Kanitakis
et al., 2000; Gualandri et al., 1999). Familial and congenital
multiple DFs are very rare but have been reported
(Pinto-Almeida et al., 2013; Marque et al., 2013).
Immunodeﬁciency, autoimmune diseases or the intake of
immunosuppressive drugs should be ruled out in patients
with multiple DFs.
The lesions represent reactive proliferation of ﬁbroblasts
usually secondary to minor trauma or an insect bite
(McKee et al., 2005). Basic ﬁbroblast growth factor and
platelet-derived growth factor levels were elevated in the
serum of patients with SLE with multiple DFs, which
stimulates ﬁbroblast proliferations, and thus explains the
increased risk of dermatoﬁbroma development
(Yamamoto et al., 1995). The role of immune suppressive
medications in the development of multiple DFs is still
unknown but could be explained by the fact that DFs
develop through an abortive immune reactive process
which can be triggered by drugs that down-regulate T cells
(Nestle et al., 1995).Because the lesions are benign, treatment is not neces-
sary. Some lesions do undergo spontaneous slow resolu-
tion. Nevertheless, treatment options include surgical
excision, pulse dye laser, or carbon dioxide laser (Alonso-
Castro et al., 2012; Wang and Lee, 2006; Wang et al.,
2013).
3. Conclusion
The most common association with multiple DFs is
found to be SLE followed by HIV infection. Most of
patients with SLE who developed multiple DFs were on
immune suppressive medications. Dermatologists, rheuma-
tologists, surgeons and internists should be aware of this
association and the clinical appearance of the lesions in





Alonso-Castro, L., Boixeda, P., Segura-Palacios, J.M., de Daniel-
Rodrı´guez, C., Jime´nez-Go´mez, N., Ballester-Martı´nez, A., 2012.
Dermatoﬁbromas treated with pulsed dye laser: clinical and dermo-
scopic outcomes. J. Cosmet. Laser Ther. 14 (2), 98–101 (PMID:
22384809).
Gualandri, L., Betti, R., Cerri, A., Pazzini, C., Crosti, C., 1999. Eruptive
dermatoﬁbromas and immunosuppression. Eur. J. Dermatol. 9 (1), 45–
47 (PMID: 9920988).
Han, T.Y., Chang, H.S., Lee, J.H., Lee, W.M., Son, S.J., 2011. A clinical
and histopathological study of 122 cases of dermatoﬁbroma (benign
ﬁbrous histiocytoma). Ann. Dermatol. 23 (2), 185–192 (PMID:
21747617).
Kanitakis, J., Carbonnel, E., Delmonte, S., Livrozet, J.M., Faure, M.,
Claudy, A., 2000. Multiple eruptive dermatoﬁbromas in a patient with
138 N.A. Al-Dawsari, N.K. Amra / Journal of Dermatology & Dermatologic Surgery 20 (2016) 135–138HIV infection: case report and literature review. J. Cutan. Pathol. 27
(1), 54–56 (PMID: 10660133).
Li, N., McNiﬀ, J., Hui, P., Manﬁoletti, G., Tallini, G., 2004. Diﬀerential
expression of HMGA1 and HMGA2 in dermatoﬁbroma and der-
matoﬁbrosarcoma protuberans: potential diagnostic applications, and
comparison with histologic ﬁndings, CD34, and factor XIIIa
immunoreactivity. Am. J. Dermatopathol. 26 (4), 267–272 (PMID:
15249855).
Lu, I., Cohen, P.R., Grossman, M.E., 1997. Multiple dermatoﬁbromas in
a woman with HIV infection and systemic lupus erythematosus.
Dermatology 195 (4), 344–348 (PMID: 7722054).
Marque, M., Pallure, V., Huet, P., Bessis, D., Guillot, B., 2013. Multiple
familial ‘‘eruptive” dermatoﬁbromas. Ann. Dermatol. Venereol. 140
(6–7), 452–454 (PMID: 23773744).
Massone, C., Parodi, A., Virno, G., Rebora, A., 2002. Multiple eruptive
dermatoﬁbromas in patients with systemic lupus erythematosus treated
with prednisone. Int. J. Dermatol. 41 (5), 279–281 (PMID: 12100703).
McKee, P.H., Calonje, E., Granter, S.R., 2005. Pathology of the Skin:
With Clinical Correlations, third ed. Elsevier Mosby, Philadelphia, pp.
1742–1752.
Naversen, D.N., Trask, D.M., Watson, F.H., Burket, J.M., 1993. Painful
tumors of the skin: ‘‘LEND AN EGG”. J. Am. Acad. Dermatol. 28 (2
Pt 2), 298–300 (PMID: 8436643).
Nestle, F.O., Nickoloﬀ, B.J., Burg, G., 1995. Dermotoﬁbroma: an
abortive process mediated by dermal dendritic cells?. Dermatology
190 265–268 (PMID: 7655103).
Niiyama, S., Katsuoka, K., Happle, R., Hoﬀmann, R., 2002a. Multiple
eruptive dermatoﬁbromas: a review of the literature. Acta Derm.
Venereol. 82 (4), 241–244 (PMID: 12361125).
Niiyama, S., Katsuoka, K., Happle, R., Hoﬀmann, R., 2002b. Multiple
eruptive dermatoﬁbromas: a review of the literature. Acta Derm.
Venereol. 82, 241–244 (PMID: 12361125).Niiyama, S., Happle, R., Hoﬀmann, R., 2004. Multiple disseminated
dermatoﬁbromas in a woman with systemic lupuserythematosus. Eur.
J. Dermatol. 11, 475–476 (Clin. Exp. Dermatol. 2004 Sep; 29(5):483–5,
PMID: 11525961).
Pinto-Almeida, T., Caetano, M., Alves, R., Selores, M., 2013. Congenital
multiple clustered dermatoﬁbroma and multiple eruptive dermatoﬁ-
bromas – unusual presentations of a common entity. An. Bras.
Dermatol. 88 (6 Suppl. 1), 63–66 (PMID: 24346882).
Rapini, R., 2005. Practical Dermatopathology, ﬁrstst ed. Elsevier Mosby,
pp. 341–342.
Tsunemi, Y., Tada, Y., Saeki, H., Ihn, H., Tamaki, K., 1995. Multiple
dermatoﬁbromas in a patient with systemic lupus erythematosus and
Sjo¨gren’s syndrome. J. Am. Acad. Dermatol. 32 (5 Pt 2), 901–903
(PMID: 15347330).
Wang, S.Q., Lee, P.K., 2006. Treatment of dermatoﬁbroma with a 600 nm
pulsed dye laser. Dermatol. Surg. 32 (4), 532–535 (PMID: 16681661).
Wang, A.S., Larsen, L., Chang, S., Phan, T., Jagdeo, J., 2013. Treatment
of a symptomatic dermatoﬁbroma with fractionated carbon dioxide
laser and topical corticosteroids. J. Drugs Dermatol. 12 (12), 1483–
1484 (PMID: 24301252).
Weedon, D., 2002. Tumors and tumor-like proliferations of ﬁbrous and
related tissues. In: Weedon, D. (Ed.), Skin Pathology. Churchill
Livingstone, London, pp. 930–934.
Yamamoto, T., Katayama, I., Nishioka, K., 1995. Involvement of basic
ﬁbroblast growth factor in ﬁbroblast-stimulatory serum activity of a
patient with systemic lupus erythematosus and multiple dermatoﬁbro-
mas. Dermatology 191, 281–285 (PMID: 8573922).
Zaballos, P., Puig, S., Llambrich, A., Malvehy, J., 2008. Dermoscopy of
dermatoﬁbromas: a prospective morphological study of 412 cases.
Arch. Dermatol. 144 (1), 75–83 (PMID: 18209171).
